JAK inhibitors in rheumatoid arthritis-associated interstitial lung disease: a review of mechanisms and clinical evidence - Report - MDSpire

JAK inhibitors in rheumatoid arthritis-associated interstitial lung disease: a review of mechanisms and clinical evidence

  • By

  • Zhiying Wu

  • Li Jiang

  • Xu Zheng

  • Wanlin Zhou

  • Zuofeng Wang

  • Weilin Xie

  • July 1, 2026

  • 0 min

Share

Clinical Report: Exploring the Role of JAK Inhibitors in RA-ILD

Overview

JAK inhibitors are being investigated as a treatment for rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Safety concerns, particularly in older patients, necessitate careful patient selection.

Background

RA-ILD is a severe manifestation of rheumatoid arthritis, significantly increasing morbidity and mortality rates. The management of RA-ILD is complex, requiring a balance between controlling joint inflammation and preventing pulmonary progression.

Data Highlights

No numerical data available in the source material.

Key Findings

  • Clinical evidence suggests that JAK inhibitors do not increase the risk of incident ILD.
  • Current evidence on JAK inhibitors in RA-ILD is primarily derived from observational studies and case series.

Clinical Implications

The use of JAK inhibitors in RA-ILD requires careful patient selection and a thorough risk-benefit assessment.

Conclusion

Further confirmatory randomized controlled trials are needed to establish the safety and efficacy of JAK inhibitors in RA-ILD.

Related Resources & Content

  1. Akiyama et al., 2022 -- Role of specific autoantibodies and genetic polymorphisms in RA-ILD
  2. Narváez et al., 2024 -- Efficacy and safety of JAK inhibitors in RA-ILD
  3. conexiant — Selective JAK Inhibition in RA vs PV
  4. Clinical Rheumatology — The Role of Osteoimmunology in Rheumatoid and Psoriatic Arthritis: Investigating Tofacitinib's Impact on Bone Health
  5. Drug Safety — Balancing Cardiovascular and Cancer Risks in the Use of JAK Inhibitors
  6. Journal of Crohn's and Colitis — Therapeutic potential of Janus kinase inhibitors for the management of fibrosis in inflammatory bowel disease
  7. Selective JAK Inhibition in RA vs PV
  8. Balancing Cardiovascular and Cancer Risks in the Use of JAK Inhibitors
  9. https://rheumatology.org/api/asset/bltaedebda97a351d47
  10. Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial - PMC
  11. Incidence of Interstitial Lung Disease in Patients With Rheumatoid Arthritis Treated With Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs | Rheumatology | JAMA Network Open | JAMA Network

Original Source(s)

JAK inhibitors in rheumatoid arthritis-associated interstitial lung disease: a review of mechanisms and clinical evidence

  • by Zhiying Wu, Li Jiang, Xu Zheng, Wanlin Zhou, Zuofeng Wang, Weilin Xie

  • July 1, 2026

Related Content

Comparison of efficacy and cost-effectiveness between mobile-bearing and fixed-bearing unicompartmental knee arthroplasty for elderly patients with knee osteoarthritis: a retrospective cohort study

Naringin and denosumab ameliorate osteoporosis and suppress the aldosterone-MR/SGK1 signaling axis by modulating the bone-kidney interorgan communication in Orchiectomized rats

Donor-dependent immunomodulatory effects of human dental pulp stem cells on macrophages